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Abstract
Background: HIV viral load testing as a component of antiretroviral therapy monitoring is costly. Understanding
the full costs and the major sources of inefficiency associated with viral load testing is critical for optimizing the
systems and technologies that support the testing process. The objective of our study was to estimate the costs
associated with viral load testing performed for antiretroviral therapy monitoring to both patients and the public
healthcare system in a low-HIV prevalence, low-resource country.
Methods: A detailed cost analysis was performed to understand the costs involved in each step of performing a
viral load test in Nicaragua, from initial specimen collection to communication of the test results to each patient’s
healthcare provider. Data were compiled and cross referenced from multiple information sources: laboratory
records, regional surveillance centre records, and scheduled interviews with the key healthcare providers
responsible for HIV patient care in five regions of the country.
Results: The total average cost of performing a viral load test in Nicaragua varied by region, ranging from US
$99.01 to US$124.58, the majority of which was at the laboratory level: $88.73 to $97.15 per specimen, depending
on batch size. The average cost to clinics at which specimens were collected ranged from $3.31 to $20.92,
depending on the region. The average cost per patient for transportation, food, lodging and lost income ranged
from $3.70 to $14.93.
Conclusions: The quantitative viral load test remains the single most expensive component of the process. For the
patient, the distance of his or her residence from the specimen collection site is a large determinant of cost.
Importantly, the efficiency of results reporting has a large impact on the cost per result delivered to the clinician
and utility of the result for patient monitoring. Detailed cost analysis can identify opportunities for removing
barriers to effective antiretroviral therapy monitoring programmes in limited-resource countries with low HIV
prevalence.
Background
Recent progress in managing antiretroviral therapy
(ART) in patients with HIV/AIDS in low-resource set-
tings has outpaced the scaling-up of tests to support
effective case management. CD4 and HIV viral load are
the two primary tests used to monitor viral suppression.
Cost-effectiveness studies are fairly concordant on the
added value of CD4 testing versus symptom-based man-
agement of patients on ART [1-4]. Less clear is the cost
effectiveness of viral load testing for management of
patients on ART [2,3,5,6]. Compared with CD4 testing,
viral load testing is more expensive and technically com-
plex. Yet there is increasing awareness of the benefit of
viral load testing both for patient management and for
public health in terms of early and accurate detection of
failure to respond to ART, thus mitigating drug resis-
tance and averting new infections [7-10].
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have focused primarily on the activities that take place
after a specimen arrives at a viral load testing facility to
the point at which the test results are generated [11-15].
The studies did not take into account patient costs, the
costs of specimen collection and transport, or added
costs resulting from inefficiencies in any aspect of the
process, both from the patient perspective and from the
specimen collection site (SCS) perspective.
In addition, most of these reports evaluating ART
strategies in low-resource settings have focused primar-
ily on sub-Saharan Africa, where the AIDS burden is
highest. These reports have ignored the challenges in
implementing a sustainable ART monitoring programme
in low-prevalence countries, which are likely to be dif-
ferent from those in high-prevalence countries.
To increase understanding of the costs of viral load
testing to patients and health systems in low-HIV preva-
lence settings, we performed a cost analysis in Nicara-
gua, a country with an adult HIV prevalence of 0.2%
(range: 0.2% to 0.4%) [16]. Our objectives were to assess
total costs, identify inefficiencies in the systems support-
ing viral load testing, and identify current and emerging
solutions that could make viral load testing more acces-
sible in low-prevalence countries.
Methods
Study sites
In collaboration with the Nicaraguan Ministry of Health,
the research team selected six SCS for data collection.
The six SCS facilities are distributed over five regions of
Nicaragua: Managua; a Pacific coast region; a central
region; and two Atlantic coast regions. With the excep-
tion of one health centre site, all are regional referral
hospitals. Data were also collected from the Centro Nacio-
nal de Diagnóstico y Referencia (CNDR) in Managua,
Nicaragua’s national reference laboratory, where all viral
load testing is performed.
Data collection
From June 2008 until June 2009, data were compiled
and cross referenced from multiple information sources:
laboratory records, regional surveillance centre records,
and scheduled interviews with the key healthcare provi-
ders responsible for HIV patient care. Patient costs were
obtained indirectly from multiple sources, including
municipal sources, Ministry of Transportation records,
hostelling sites, and non-governmental organizations
working with HIV patients. We used direct observation
to estimate the resources used for viral load testing, and
accessed CNDR administrative records to obtain 2008
purchase costs for testing supplies.
Input, resource use and unit cost data were collected
for the following steps and activities:
1. Patients travelling to collection sites and providing a
sample for viral load and CD4 testing.
2. Health workers collecting the specimen at a speci-
men collection site (SCS) to obtain a 10 ml blood sam-
ple for the viral load test.
3. Health workers at the SCS shipping the specimen to
the testing facility.
4. Laboratory workers performing the viral load
testing.
5. Testing facility staff communicating test results to
the ART managing facility. These data were not col-
lected directly, but were included in the administrative
costs at the CNDR, Sistemas Locales de Atención Inte-
gral en Salud (SILAIS, Local System of Integrated
Health Care), the SCS and the ART management
facility.
Cost categories
For our analysis, we estimated the cost of viral load test-
ing that accrued to three parties: the patient; the clinic
or hospital at which the specimen was collected; and the
laboratory at which the test was performed.
Patient costs
We estimated patient costs associated with transporta-
tion to and from the SCS, the purchase of food that
otherwise would not have been purchased as part of the
daily routine, overnight accommodations (if necessary),
and lost income as a result of taking the time to have
the specimen collected. To evaluate the full range of
patient experiences, these costs were calculated for
patients from all regions served by the respective SCS
facilities.
To facilitate comparison between regions and to cal-
culate the average patient cost nationally, we estimated
weighted average patient costs based on the place of
residence. The weighted average patient cost was calcu-
lated by multiplying the average cost per patient from
each location by the number of patients from each loca-
tion. Thus, if 80% of patients lived near the SCS and
only 20% were remote, the weighted average cost would
be closest to the cost for those who lived near the SCS.
Clinic/hospital costs (SCS)
SCS costs included labour associated with all required
staffing levels, specimen collection supplies, specimen
transport and storage supplies, and annualized deprecia-
tion costs for capital equipment. Additional costs
included accommodations and/or food when the clinic
provided these to the patient.
Supplies included the full range of materials used to
collect and transport the specimen, including latex
gloves, vacutainers, waste disposal boxes, and thermoses
for cold transport. Labour was broken into the following
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processing); site preparation; patient counselling; and
specimen collection, processing and packaging. Trans-
port costs for shipping the specimen to the testing facil-
ity included labour for a driver, fuel consumption,
vehicle depreciation and airfare (if necessary). Since HIV
prevalence is low in Nicaragua, the overhead costs attri-
butable to ART management are low in comparison
with all other hospital costs. Overhead facility costs
therefore were not represented in the analysis.
Laboratory costs
The team collected information on inputs for resources
and unit costs associated with specimen processing and
viral load testing, such as laboratory supplies and equip-
ment and waste management. At the national lab, the
CNDR performed viral load testing with the Roche
Molecular Diagnostics COBAS® Amplicor test kit until
the end of 2009. The 2008 price to the CNDR for the
purchase of COBAS® Amplicor reagents was used in this
cost analysis. To determine labour and materials at this
level, we conducted a time and motion study of labora-
tory procedures for viral load testing. Laboratory costs
were classified as labour, annualized depreciation for
capital equipment, disposable supplies (including test
kits), and facility overhead costs.
In addition, we captured information on mean time
for results to be delivered from the CNDR reference
laboratory to the SCS, the percentage of samples col-
lected at the SCS for which results were returned to the
SCS from the CNDR, and estimates on loss to follow
up. Data for the results returned to the SCS were col-
lected from laboratory and SCS records. Specifically, we
collected data to calculate the number of runs per-
formed per month, the number of tests performed per
month, the average number of tests per run, the maxi-
mum delay in performing tests, the level of batching,
and the labour time to perform a viral load test (includ-
ing the sub-steps). Anecdotal estimates on loss to follow
up were obtained from the ART multidisciplinary team
at the SCS.
The costs associated with communicating test results
back to the ART managing facility were included in the
administrative costs of the CNDR, the SILAIS and the
ART management facility.
Data analysis
We developed a Microsoft Excel-based cost model to
estimate: (1) the per-patient cost per specimen collected;
(2) the per-SCS cost per specimen collected; and (3) the
cost per test performed at the CNDR laboratory.
In addition, we developed a module that took into
account the number of tests in each kit configuration
and the laboratory’s specific throughput (number of
tests run). This allowed us to vary the laboratory costs
depending on batch size. The CNDR laboratory typically
uses optimal batch sizes for viral load testing. Using spe-
c i f i cd a t af r o mt h el a b o r a t o r yo ni t so p t i m a lb a t c hs i z e
(i.e., the number of specimens per batch), we estimated
the laboratory cost per test performed based on varying
batch sizes, from one to 24 specimens. An optimal
batch size is 22 specimens. Running a batch of 10 speci-
mens is more cost effective than running batches with
11 to 19 specimens. Ten and 22 specimen batches are
possible when including only two controls (one negative
and one positive) per run. Thus, for the CNDR labora-
tory, we estimated a typical batch run as either 10 or 22
specimens, depending on demand for testing.
After calculating the cost per specimen collected and
viral load test performed, we calculated: (1) the cost per
result delivered to the SCS; and (2) the total cost per
result delivered to inform patient care.
At the SCS level, we calculated the cost per viral load
test result communicated back to the SCS, using rates
of attrition for specimens sent to the CNDR and results
returned to the SCS as obtained from laboratory and
SCS records. To calculate the cost per viral load test
result communicated back to the patient, we used rates
for loss to follow up collected from records or anecdo-
tally at the SCS.
Human subjects and research determination
This study was reviewed by the Programs for Appropri-
ate Technologies in Health (PATH) Research Determi-
nation Committee. Informed consent was not required,
as the data were collected from public records and ana-
lyzed anonymously. Patients were not interviewed or
contacted for data collection, and no human identifiers
were collected.
Results
Viral load testing in Nicaragua
In May 2008, ART distribution in Nicaragua was decen-
tralized to 16 hospitals and three health centres
throughout the country. As of November 2008, 78% of
the SILAIS facilities provided ART. National regulations
provide for viral load and CD4 testing every six months
for each HIV patient. At the time of this study, the
C N D Ri nM a n a g u aw a st h eo n l yl a b o r a t o r yp e r f o r m i n g
viral load measurements and CD4 determinations. Thus,
all specimens were sent to the CNDR laboratories in
Managua for CD4 and viral load testing.
Specimens were collected at SCS facilities for both
CD4 and viral load testing. Three EDTA-K3 BD vacutai-
ners® of blood were collected: one for CD4 and two for
viral load. The vacutainers were sent to the CNDR
laboratories on ice and had to arrive within six hours of
collection time to be considered valid. CD4 tests were
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collection tubes for viral load were centrifuged upon
arrival to the CNDR and the plasma from the samples
stored at -70°C. Plasma samples were allowed to accu-
mulate until they could be batched in the viral load
assay for optimal throughput testing. The CD4 and viral
load test results were independently entered into a
report that was communicated to the originating
SILAIS, which then communicated the results to the
ART multidisciplinary team. ART management may or
may not have occurred at the same site as specimen col-
lection (Figure 1).
For this study, detailed cost data were collected from
six nationwide SCS facilities and the CNDR laboratory.
The SCS facilities represent urban, rural and remote set-
tings, with four sites representing regions with urbaniza-
tion levels of 30% or less. Each site submitted between
30 and 330 specimens for viral load testing in 2008.
Total cost per test
Table 1 shows a summary of the costs per test per-
formed to patients, the SCS and the viral load testing
laboratory. The costs ranged from $99.01 to $124.58. In
all cases, laboratory costs represented the greatest share
of the total cost. There was some variability in the per-
centage of the total cost per patient versus the percen-
tage of the total cost per SCS across regions. On
average, however, the overall cost per patient was simi-
lar to the overall cost per SCS (Figure 2).
Patient costs
Minimum and maximum costs indicate that proximity to
the SCS is the main driver of cost to patients (Table 2),
with transportation being the main cost contributor.
Larger urban sites with a small minority of patients living
in remote areas had lower weighted average patient costs
(e.g., Site 1). In contrast, in more rural regions, where a
larger proportion of patients live in remote areas, the
weighted average patient cost was as high as $14.93.
The majority of patients - that is, those who live near the
clinic - bear a cost well below the average patient cost,
whereas the minority of patients who live in remote areas
bear a cost well above the average. Overall, 65% of the
patients bear a cost of less than $5 for providing a sam-
ple, and 95% bear a cost of less than $10. In the Atlantic
regions, the terrain imposes significant access challenges,
requiring patients to spend up to three days to complete
Specimen 
collection 
site
ART case 
management 
site
ART multi-
disciplinary 
team
CNDR
CD4 and 
viral load 
testing site
SILAIS
Patient
Figure 1 Summary of process for CD4 and viral load testing.
The patient goes to the SCS (solid arrow) to have blood drawn. The
specimen is shipped under the cold chain to the central laboratory
(CNDR) for CD4 and viral load testing (double-line arrow). Results
are communicated (dotted arrow) back to the originating local
healthcare department (SILAIS). The SILAIS then communicates the
results back to the pertinent ART multidisciplinary team. The SCS,
ART multidisciplinary team and ART case management site (gray
shading) may or may not reside at the same healthcare facility.
Patient 
(9%)
Central testing 
facility 
(82%)
Specimen 
collection site 
(9%)
Figure 2 Relative patient, SCS and central testing facility costs
to perform an HIV viral load test.
Table 1 Total patient, SCS and laboratory costs per viral
load test performed, by site (US dollars)
SCS site 1 2 3456
Patient 3.70
(3.7%)
8.90
(8.8%)
8.78
(8.5%)
10.27
(9%)
14.93
(12%)
14.62
(13%)
Clinic 6.58
(6.7%)
3.31
(3.3%)
6.41
(6.1%)
14.97
(13.1%)
20.92
(16.8%)
9.48
(8.4%)
Laboratory* 88.73
(88.6%)
88.73
(87.9%)
88.73
(85.4%)
88.73
(77.9%)
88.73
(71.2%)
88.73
(78.6%)
Total 99.01 100.94 103.92 113.97 124.58 112.83
*Calculated using the optimal 22 specimens perrun.
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between patient distance from the SCS at one Atlantic
coast site and cost to the patient is shown in Figure 3A.
Specimen collection site costs
Our analysis shows that the cost per test performed at
the SCS ranged from $3.31 to $20.92 (Table 3). The lar-
gest contributors to cost differences for the SCS were
transport and labour, although there were significant
differences in costs for supplies and patient accommo-
dations/food. Sites 5 and 6 experienced the highest
transportation costs because they had to dispatch the
specimens to the CNDR by air. Batching specimen col-
lection and shipment achieved a lower cost per speci-
men (Sites 5 and 6). A direct relationship between
distance of the SCS and the central laboratory and the
costs was not observed (Figure 3B).
Viral load testing laboratory costs
The CNDR used the Roche COBAS® Amplicor test kit
until 2009. The test kit’s packaging and performance are
configured to create economies of scale (data not shown).
The optimal batch sizes and those performed by the
laboratory are 10 or 22 specimen batches. Table 4 shows
the per-specimen costs for batches of these sizes. The
cost of the COBAS® Amplicor test kit accounted for 90%
of the cost of performing each test.
Facilities and equipment were the next largest contri-
butors to cost, accounting for approximately 6%. Labour
and disposables accounted for roughly 4% of the cost of
performing the test.
Cost of delivering test results
Table 5 shows the cost of delivering the viral load test
results to the SCS and the patient, based on specific
Table 2 Patient costs, by site (US dollars)
SCS site 1 2 3 4 5 6
Transportation* 1.23
(0.42/4.50)
1.54
(0.42/3.83)
2.13
(0.42/3.83)
2.85
(0.37/7.73)
6.64
(1.05/40.05)
5.68
(1.05/105.20)
Lodging* 0.1
(0/0.10)
1.74
(0/4.34)
1.16
(0/6.31)
0
(0/0)
2.28
(0/6.48)
1.78
(0/23.67)
Food* 0.86
(0.81/1.10)
2.26
(1.05/3.42)
3.37
(1.58/5.52)
2.17
(1.05/3.42)
3.37
(0/11.67)
4.63
(2.63/26.83)
Lost income* 1.40
(0.91/3.42)
3.36
(1.31/5.25)
2.12(1.06/4.25) 2.39
(0.42/6.66)
2.64
(0.0/10.82)
2.54
(1.15/18.44)
Total weighted average 3.70 8.90 8.78 10.27 14.93 14.62
Total median 2.14 5.88 7.71 8.13 1.69 4.83
Min/max 2.14/8.97 2.78/16.85 3.07/19.92 2.20/25.54 1.05/69.03 4.83/174.14
*Minimum and maximum costs are provided in parentheses.
0
10
20
30
40
50
60
70
80
0 100 200
0
10
20
30
40
50
60
70
80
0 100 200
C
o
s
t
 
(
U
S
$
)
C
o
s
t
 
(
U
S
 
$
)
Distance from specimen 
collection site (km)
Distance from Managua  
(km)
A. Patient costs B. Costs to health care system
0
20
40
60
80
100
120
0 100 200 300 400
0
20
40
60
80
100
120
0 100 200 300 400
Figure 3 Relationship between costs and distance. 3A. The distance from home to the SCS for HIV patients in the Atlantic regions. Empty
squares represent the direct transportation costs incurred by patients. Filled squares represent fully burdened food, lodging and opportunity
costs to patients. 3B. The distance from the SCS to the central testing facility (in Managua). Empty squares represent specimen transport costs.
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contrast with the costs to patients, the SCS and the test-
ing laboratory (which ranged from $99.01 to $124.58,
including administrative costs), the total cost per viral
load test result returned to the SCS ranged from
$100.94 to $153.80. These figures were based on total
attrition rates obtained from the number of specimens
sent to the central laboratory and the number of results
returned to the SCS. It thus included both rejected sam-
ples and inefficiencies in results reporting.
We recorded the time lapse for result delivery based
on specimen shipment dates and result receipt dates at
the SCS. The mean time for test result delivery per
region ranged from 15 to 60 days and was not related
to distance of the SCS from the CNDR laboratory in
Managua. The time delay in test result delivery impacted
the use of the results in informing treatment decisions, as
well as actual delivery of the results to the patient. The
total cost per result delivered to the patient was based on
records and anecdotal data. Attrition in the results deliv-
ery process increased the cost per delivered test result by
11% to 33%, depending on the site (Table 5).
Discussion
The aim of this study was to obtain a detailed cost pro-
file for the process of HIV viral load testing in Nicara-
gua in order to identify inefficiencies in the systems that
support viral load testing. With this information, we
sought to identify opportunities to maximize access to
viral load testing and generate evidence on the role of
new and appropriate technologies.
Cost implications for patients
The patient’s cost burden for providing a specimen for
ART monitoring is significant. On average, it is equiva-
lent to the cost per specimen at the SCS (Figure 2).
Patient cost is also subject to the greatest variability. In
this study, we considered only travel costs, lodging and
opportunity costs (as defined by days of work lost) as a
result of providing a specimen. Based on these factors,
the patient’s distance from the SCS had the biggest
impact on the cost of specimen collection for viral load
testing, more than the distance of the SCS to the CNDR
in Managua (Figure 3). The average monthly incomes in
the regions where the study was performed were
between $90 and $117 per month at the time of the
study, so average patient costs of $3.70 to $14.93 is a
significant burden to the patient.
For patients in remote regions, ART management has
been decentralized to local healthcare providers, which
means that patients do not need to travel to the SCS for
ART. While this study did not examine adherence and
reasons for failing to adhere to ART, other studies have
shown that travel from the patient’sh o m et ot h eA R T
clinic is a major barrier [17-19]. In a similar way, our
data suggest that programmes seeking to increase access
to ART monitoring tests must consider patient costs,
which can present a major barrier to testing compliance.
Table 4 CNDR laboratory costs for running viral load
tests (US dollars)
Batch of 10
specimens
Batch of 22
specimens
Reagents (Amplicor test kit) 87.50 79.55
Disposables
Specimen aliquoting 0.19 0.17
RNA extraction 1.39 1.22
PCR reaction preparation 1.27 1.16
Total disposables 2.85 2.54
Labour
Specimen receipt and
processing
0.06 0.04
RNA extraction 0.23 0.19
PCR reaction preparation 0.12 0.06
Results processing 0.11 0.07
Administration 0.47 0.47
Data entry 0.20 0.20
Total labour 1.03 1.19
Facilities and equipment 5.62 5.62
Total cost per specimen 97.15 88.73
Table 3 SCS costs, by site (US dollars)
SCS site 1 2 3 4 5 6
Supplies 1.80 0.56 0.59 0.90 0.61 0.50
Labour 4.66 0.66 1.66 5.66 6.66 7.66
Patient accommodations 0 0 0 2.77 2.89 0
Transport 0.13 2.10 4.16 5.64 10.76 1.33
Total 6.58 3.31 6.41 14.97 20.92 9.48
Table 5 Total health system cost per test results
delivered to the SCS and to the patient
SCS Minimum Mean Median Maximum
% of results successfully
delivered to the SCS
81% 93% 92.5% 100%
Total cost per results
delivered to SCS (US$)
100.94 118.94 114.08 153.80
% of results delivered to
the patient
80% 88% 90% 99%
Total cost per results
delivered to patient (US$)
112.15 134.63 135.48 155.35
Increase in cost due to
attrition in results delivered
11% 23% 24% 33%
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The viral load test itself remains the single most expen-
sive component of the whole testing process, represent-
ing approximately 80% of the total costs. The CNDR in
Nicaragua used the Roche COBAS® Amplicor test kit
during 2009. Given the limited viral load testing volume,
there is no justification for housing multiple platforms
in Nicaragua. Nicaragua does not have access to Clinton
Foundation-negotiated prices, but even at a reagent cost
of approximately $20 per specimen, the reagents would
remain the most expensive part of the process. Procure-
ment arrangements most significantly impact the abso-
lute cost of viral load testing, as has also been discussed
to be the case for CD4 testing [20]. Additionally, as
demonstrated previously in a detailed cost analysis for
viral load testing, the number of specimens tested per
run can be the most impactful variable on the cost per
reportable tests result [11,13].
Cost-saving opportunities could result from the adop-
tion of lower-cost real-time polymerase chain reaction
(PCR) tests or the Cavidi ExaVir® reverse transcriptase
assay [14,21-23]. We calculated, as described for the
Roche test, the cost of performing the ANRS homebrew
real-time PCR test [14,21] in Nicaragua to be $21.92 per
specimen, compared with $88.73 for performing the
commercial test under current prices (unpublished data).
It should be noted, however, that the challenges of multi-
ple vendor sourcing for different test components and
additional import costs may lower the cost benefit of
such a solution [24].
Test results delivery
Delivery of the test results back to the patient’sA R T
healthcare provider is a critical component of the full test-
ing process. The efficiency of this process is in part deter-
mined by the percentage of results that are successfully
delivered to the healthcare provider. A higher-efficiency
communication of test results would reduce the cost per
successfully delivered test result. In addition, faster deliv-
ery of test results may increase the healthcare provider’s
active use of the results and inform ART management.
Due to the high costs involved in performing the viral
load test, any attrition in the test result delivery process
has a large impact on the total cost per reported result.
Interestingly, we found that this process had a much
higher attrition rate than specimen shipment under the
cold chain. As shown in Table 5, although the efficiency
of the process from the CNDR and SCS laboratory
r e c o r d si sh i g h( >8 0 % ) ,t h i sh a sal a r g ei m p a c to nt h e
overall cost per reported test result. Further attrition is
observed when taking into consideration the patient’s
need to return for the results, although the anecdotal
nature of these reports means that there is less certainty
in these numbers.
A related issue is the time lapse between performance
of the viral load test and delivery of the results to the
patient’s ART healthcare provider. To further investigate
this delay, we mapped the process for returning the viral
load test results to the healthcare provider. There is sig-
nificant variation in the process, and depending on the
specimen’s region of origin, a minimum of five or seven
information transfers is involved. In contrast with speci-
men shipment from the SCS to the CNDR, where the
SCS laboratory is responsible for successful delivery of
the specimen, the result reporting system has several
intermediaries, possibly explaining the attrition rates
and delays in result reporting.
The long lapse between specimen collection and test
result delivery may limit the role of the test results in
actively informing ART management. Quantifying this
impact may be critical for evaluating the effectiveness of
viral load testing in ART monitoring strategies.
Limitations due to cold chain requirements
The cold chain requirements for specimen preservation
(and the maximum time lapse of six hours from speci-
men collection to arrival at the CNDR testing facility)
mean that specimen collection cannot be decentralized,
with the biggest cost impact falling on the patient. Such
technologies as the use of dry filter spots (i.e., dried
blood spots) could overcome this challenge. Alternately,
a robust low- to medium-throughput platform that
could be run at the SCS would meet the needs of most
patients (95%, at a per-patie n tc o s to fl e s st h a n$ 1 0 ) .
Such technologies are beginning to emerge [23,25].
Waste management
The study results allowed us to project some implica-
tions of decentralization of viral load testing on waste
management. In the centralized testing system, the
majority of waste, which includes specimen vacutainers
and disposables and chemicals for performing the test,
is contained at the CNDR laboratory. Other researchers
have shown that the cost of waste disposal for viral load
testing is less than 0.1% of the total cost, or $0.01 to
$0.07 per test [11]. Althought h i sc o s ti sm i n i m a l ,i ti s
important to note that any decentralization of viral load
testing will significantly increase the biohazardous, che-
mical and nonhazardous waste at decentralized facilities,
which in turn could require waste management capacity
building.
Study limitations
The methods used to collect data in this study present
several limitations. Most critically, patients were not
approached for this study, so data regarding patient
costs are based on anecdotal scenarios, local transpor-
tation and accommodation costs, and average local
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Page 7 of 9earnings. Also, the study did not collect specific cost
and time information regarding communication of
results to the patient. Furthermore, the process was
mapped only as far as communication of the viral load
test results to the healthcare provider managing the
patient. Although data were collected by the same
researchers at all sites, the results reporting data were
collected by informal interview and from laboratory
records, which may have underestimated the administra-
tive costs of the testing process. Also, staff training costs
and waste management costs were not included in the
study.
Conclusions
Nicaragua has implemented an efficient viral load and
CD4 testing system for patients on ART. The largest
variables in the overall viral load testing cost were the
patient’s proximity to the SCS and the cost of viral load
testing itself.
Patients living in remote settings face the highest test-
ing costs. Any efforts to increase access to viral load test-
ing must take into consideration patient transportation
and opportunity costs as potential barriers. The process
by which results are communicated to the healthcare
provider managing the ART regimen is especially impor-
tant, as the efficiency of this process has a large impact
on the total cost per successfully delivered test result.
Additionally, because the time between result generation
and result communication affects how the results are
used, decreasing this time would be beneficial.
With regard to viral load testing, if optimal specimen
batching is routinely performed at the central labora-
tories, the single most expensive component of the pro-
cess is the price of the commercial viral load test to the
programme. Additionally, a low-throughput device of 10
to 12 specimens per run (appropriate for use at the SCS),
in combination with specimen stabilization technologies,
such as one using dried blood spots [26], could overcome
some inefficiencies in the current system.
Increasingly, there is recognition that no single health
system change or technology solution will meet the
diverse needs related to HIV viral load testing [24,27-29].
Detailed operational research is required to unravel cur-
rent inefficiencies and barriers in ART monitoring and to
define the portfolio of technologies and system strength-
ening opportunities that will address these issues.
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